Skip to main content
SK Bioscience Co.,Ltd logo

SK Bioscience Co.,Ltd — Investor Relations & Filings

Ticker · 302440 ISIN · KR7302440003 KO Manufacturing
Open in API
Filings indexed 383 across all filing types
Latest filing 2023-09-12 Director's Dealing
Country KR South Korea
Listing KO 302440

About SK Bioscience Co.,Ltd

https://www.skbioscience.com/

SK Bioscience is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines and biological products. Spun off from SK Chemicals in 2018, the company develops its own pipeline of vaccines, including cell-culture-based influenza vaccines and a COVID-19 vaccine, utilizing its established R&D and production platforms. In addition to its proprietary products, SK Bioscience provides global Contract Development and Manufacturing Organization (CDMO) services, offering end-to-end support from process development to large-scale commercial manufacturing for international partners. The company is dedicated to promoting public health by providing innovative preventative solutions to address global health challenges.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/Korea Exchange). This type of filing is specifically used to report insider transactions, such as share acquisitions or disposals by company directors or major shareholders. In the provided taxonomy, this corresponds to 'Director's Dealing'.
2023-09-12 Korean
투자판단관련주요경영사항(COVID-19 백신 스카이코비온(GBP510)의 유럽의약품청(EMA) 조건부허가(CMA) 신청 철회 결정)
Regulatory Filings Classification · 1% confidence The document is a regulatory disclosure from SK Bioscience regarding the withdrawal of a conditional marketing authorization application for their COVID-19 vaccine (SKYCovion) with the European Medicines Agency (EMA). This is a specific corporate event disclosure regarding business strategy and regulatory status, which does not fit into financial reporting, dividend, or governance categories. As it is a formal regulatory announcement of a material business decision, it falls under the 'Regulatory Filings' (RNS) category.
2023-09-01 Korean
대규모기업집단현황공시[분기별공시(개별회사용)]
Regulatory Filings Classification · 1% confidence The document is a 'Corporate Group Status Disclosure' (기업집단현황공시) filed by SK Bioscience. It follows a standard regulatory format for reporting group status, inter-company transactions, and governance-related disclosures (ESG) as required by Korean fair trade regulations. Since it is a specific regulatory disclosure filing that does not fit into financial reporting, proxy, or dividend categories, it is best classified as a Regulatory Filing (RNS).
2023-08-31 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 1% confidence The document is a formal regulatory disclosure from SK Bioscience regarding the signing of a significant supply contract for influenza vaccine raw materials. It details the contract value, counterparty, duration, and terms. Since this is a specific corporate event disclosure (a material contract announcement) that does not fit into categories like earnings releases, financial reports, or shareholder meetings, it falls under the general regulatory filing category.
2023-08-21 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 1% confidence The document is a '반기보고서' (Semi-annual Report) for SK Bioscience, covering the period from 2023.01.01 to 2023.06.30. It contains detailed financial information, business operations, management discussions, and corporate governance details. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year (like a half-year report) is classified as an Interim/Quarterly Report (IR). H1 2023
2023-08-11 Korean
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Regulatory Filings Classification · 1% confidence The document provides specific financial disclosure data regarding payment methods, payment periods, and dispute resolution mechanisms for SK Bioscience. This type of detailed operational and financial disclosure, which does not constitute a full financial report, earnings release, or management announcement, is typically filed as a regulatory disclosure in the Korean market (DART system). Given the lack of a better fit among the specific categories, it falls under the general regulatory filing category.
2023-08-11 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.